相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Black Hairy Tongue After Immune Checkpoint Inhibitors in NSCLC: A Case Report and Review of the Literature
Cristina Cecchi et al.
CLINICAL LUNG CANCER (2021)
Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review
Juan Francisco Pena-Cardelles et al.
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL (2021)
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series
Muhammad Ali Shazib et al.
ORAL DISEASES (2020)
Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
Mioko Matsuo et al.
ORAL ONCOLOGY (2020)
Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series
Lisa M. Morris et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2020)
S0376 Clinical Characteristics and Outcome of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer
Jake Jacob et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review
Nirav Shah et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study
Soo-Young Yoon et al.
LUNG CANCER (2020)
Strategies for improving the management of immune-related adverse events
Aung Naing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis
Goda Daugelaite et al.
MEDICINA-LITHUANIA (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
Blake M. Warner et al.
ONCOLOGIST (2019)
The pathogenesis of mucositis: updated perspectives and emerging targets
J. Bowen et al.
SUPPORTIVE CARE IN CANCER (2019)
Photobiomodulation Therapy in the Treatment of Oral Mucositis, Dysphagia, Oral Dryness, Taste Alteration, and Burning Mouth Sensation Due to Cancer Therapy: A Case Series
Marwan El Mobadder et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Incidence of and risk factors for development of oral mucositis in outpatients undergoing cancer chemotherapy
Seher Cakmak et al.
INTERNATIONAL JOURNAL OF NURSING PRACTICE (2019)
Photobiomodulation with low-level laser therapy reduces oral mucositis caused by head and neck radio-chemotherapy: prospective randomized controlled trial
F. Marin-Conde et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2019)
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
Adriana T. Lopez et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection
J. J. Varghese et al.
JOURNAL OF DENTAL RESEARCH (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Nivolumab-induced sialadenitis
Saeko Takahashi et al.
RESPIROLOGY CASE REPORTS (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M. H. Pollack et al.
ANNALS OF ONCOLOGY (2018)
Dysgeusia and health-related quality of life of cancer patients receiving chemotherapy: A cross-sectional study
E. Ponticelli et al.
EUROPEAN JOURNAL OF CANCER CARE (2017)
Impact of low-level laser therapy on hyposalivation, salivary pH, and quality of life in head and neck cancer patients post-radiotherapy
Luiz Felipe Palma et al.
LASERS IN MEDICAL SCIENCE (2017)
Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis
Heliton S. Antunes et al.
ORAL ONCOLOGY (2017)
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Vincent Sibaud et al.
CURRENT OPINION IN ONCOLOGY (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
Kurt B. Schaberg et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2016)
Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions
George Jour et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2016)
Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma
Namrata Nayar et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Microbiota and their role in the pathogenesis of oral mucositis
B. Vanhoecke et al.
ORAL DISEASES (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Efficacy and Safety of an Intraoral Electrostimulation Device for Xerostomia Relief A Multicenter, Randomized Trial
Frank P. Strietzel et al.
ARTHRITIS AND RHEUMATISM (2011)
分享论文
